GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia

Cytotherapy

Volumn 9, Issue 5, 2007, Pages 499-507

  Turin, I ^a   Pedrazzoli, P ^b   Tullio, C ^b   Montini, E ^a   La Grotteria, M Carmela ^b   Schiavo, R ^b   Perotti, C ^a   Locatelli, F ^a,c   Carretto, E ^a   Maccario, R ^a   Siena, S ^b   Montagna, D ^a,c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Adoptive immunotherapy; Cytotoxic T cells; GMP; Solid tumors

Indexed keywords

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD8 ANTIGEN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; APOPTOSIS; ARTICLE; AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL STIMULATION; CELL VIABILITY; CLEAR CELL CARCINOMA; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MEGADOSE; EFFECTOR CELL; EWING SARCOMA; FEASIBILITY STUDY; FEMALE; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CANCER; LEIOMYOSARCOMA; LYMPHOCYTOTOXICITY; NATURAL KILLER CELL; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SOLID TUMOR;

ADULT; ANTIGENS, CD8; CARCINOMA; CELL CULTURE TECHNIQUES; CELL LINE; CELL PROLIFERATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; HLA ANTIGENS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; SARCOMA; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 34548587281     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240701405428     Document Type: Article

References (21)

1. Offringa, R. (2005) Tumour immunology exploitation of the weapon of immune destruction for cancer therapy: Taking aim before firing. Curr Opin Immunol, 17, pp. 159-162.
2. Rosenberg, SA. (2001) Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med, 250, pp. 462-475.
3. Liu, SH, Zhang, M. and Zhang, WG. (2005) Strategies of antigen-specific T-cell-based immunotherapy for cancer. Cancer Biother Radiopharm, 20, pp. 491-501.
4. Brentjens, R., Latouche, JB and Santos, E. (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nature Med, 9, pp. 279-286.
5. + T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. PNAS, 99, pp. 16168-16173.
6. Phan, GQ, Yang, JC and Sherry, RM (2003) Cancer regression and autoimmunity induced by cytotoxic T-lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA, 100, pp. 8372-8377.
7. Dudley, ME, Wunderlich, JR and Yang, JC (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 23, pp. 2346-2357.
8. Dudley, ME, Wunderlich, JR and Robbins, PF (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298, pp. 850-854.
9. Melief, CJ, Toes, RE and Medema, JP (2000) Strategies for immunotherapy of cancer. Adv Immunol, 75, pp. 235-282.
10. Schnurr, M., Scholz, C. and Rothenfusser, S. (2002) Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and T cells. Cancer Res, 62, pp. 2347-2352.
11. Kurokawa, T., Oelke, M. and Mackensen, A. (2001) Induction and clonal expansion of tumor specific cytotoxic lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer, 91, pp. 749-756.
12. Montagna, D., Schiavo, R. and Gibelli, N. (2004) Ex vivo generation and expansion of anti-tumor cytotoxic T-cell lines derived from patients or their HLA-identical sibling. Int J Cancer, 110, pp. 76-86.
13. Croce, MV, Colussi, AG and Segal-Eiras, A. (1998) Assessment of methods for primary tissue culture of human breast epithelia. J Exp Clin Cancer Res, 17, pp. 19-26.
14. Freshney, RI. (1985) Induction of differentiation in neoplastic cells. Anticancer Res, 5, pp. 111-116.
15. Montagna, D., Maccario, R. and Locatelli, F. (2001) Ex vivo priming for long term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood, 98, pp. 3359-3366.
16. Sallusto, F., Lening, D. and Forster, R. (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature, 401, pp. 708-712.
17. Sallusto, F., Jenginat, J. and Lanzavecchia, A. (2004) Central memory and effector memory T cell subsets: Function generation and maintenance. Annu Rev Immunol, 22, pp. 745-763.
18. Montagna, D., Locatelli, F. and Moretta, A. (2004) T lymphocytes of recipient origin may contribute to the recovery of specific immune response towards viruses and fungi in children undergoing cord blood transplantation. Blood, 103, pp. 4322-4329.
19. + memory T cell subsets in response to antigen or homeostatic cytokines. Blood, 101, pp. 4260-4266.
20. + T cells confer superior antitumor immunity compared with effector cells. PNAS, 102, pp. 9571-9576.
21. Wherry, EG, Teichhgraber, V. and Becker, TC (2003) Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol, 4, pp. 225-234.